A biotechnology company leveraging pioneering computational methods to develop novel therapeutics, Oxford Drug Design has closed a $5.0M Series A funding round.
The advanced spinout from Oxford University focuses on designing innovative drugs with differentiated modes of action against cancer and other challenging diseases where patient outcomes need significant improvement. Its distinctive drug discovery platform uniquely integrates AI/ML methods with expertise in aminoacyl-tRNA synthetase enzymes, allowing for the rapid discovery of novel therapeutic candidates.
.png&w=3840&q=75)
